Plain-English translation of NCT07121946 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called , which is a type of antibody designed to help your immune system recognize and destroy lymphoma cells. The treatment works by attaching to cancer cells and triggering your body's own immune cells to attack them. Researchers want to find the right dose and learn more about how safe and effective this medication is for people whose lymphoma has come back or stopped responding to previous treatments.
Many patients with non-Hodgkin lymphoma eventually develop cancer that no longer responds to standard treatments, leaving them with limited options. This trial exists to explore whether this new approach to activating the immune system could offer hope to those patients.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive the medication through an IV infusion and may be part of a group testing a specific dose level. The trial lasts up to 54 weeks, during which you'll have regular visits for infusions, blood tests, and scans to check how your lymphoma is responding and monitor for any side effects. Depending on which group you're in, you may be among the first to receive a dose, or you may join after doctors have determined a dose is safe.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States